Indaptus Therapeutics, Inc.
NASDAQ:INDPBiotechnology
Healthcare
$3.29 -2.21%
-$0.03 today
- Market cap
- $372.57M
- Beta
- 1.14
- P/E (TTM)
- -0.2
- EPS (TTM)
- -$8.70
52W Low $0.92High $8.69
Volume 0.17M
Average 0.97M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$14.82M
FY 2025 · Annual
Investing Cash Flow
$0.00
FY 2025 · Annual
Financing Cash Flow
$17.54M
FY 2025 · Annual
+269.5% YoYCash Flow Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (7.71M) | (14.32M) | (15.42M) | (15.02M) | (20.85M) |
| Depreciation & Amortization | 1.4K | 1.78K | 1.28K | 735 | 0 |
| Deferred Income Tax | (5.75M) | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 1.51M | 2.96M | 2.97M | 2.31M | 1.36M |
| Change in Working Capital | (5.09M) | (1.58M) | (518.07K) | 392.26K | 3.51M |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | (4.24M) | (1.15M) | (680.52K) | 474.06K | 2.85M |
| Other Working Capital | (854.15K) | (425.59K) | 162.45K | (81.8K) | 665.3K |
| Other Non-Cash Items | 5.75M | (134.16K) | (430.99K) | 0 | 1.15M |
| Operating Cash Flow | (11.29M) | (13.08M) | (13.41M) | (12.32M) | (14.82M) |
| Capital Expenditures | (3.85K) | (172.56K) | 0 | 0 | (4) |
| Acquisitions (Net) | 451.6K | 172.56K | 0 | 0 | 0 |
| Purchases of Investments | 0 | (29.6M) | (6.86M) | 0 | 0 |
| Sales of Investments | 0 | 13M | 24M | 0 | 0 |
| Other Investing Activities | 0 | 172.56K | 0 | 0 | 0 |
| Investing Cash Flow | 447.75K | (16.43M) | 17.14M | 0 | 0 |
| Debt Repayment | 0 | 0 | 0 | 0 | 5.71M |
| Common Stock Issued | 5M | 0 | 0 | 5.51M | 11.83M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 43.34M | 0 | 0 | (762.7K) | 0 |
| Financing Cash Flow | 48.34M | 0 | 0 | 4.75M | 17.54M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 37.49M | (29.51M) | 3.74M | (7.58M) | 2.72M |
| Free Cash Flow | (11.29M) | (13.25M) | (13.41M) | (12.32M) | (14.82M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$20.8M
+ D&A$0
+ Stock-Based Comp$1.4M
+ Deferred Tax$0
+ Working Capital$3.5M
+ Other Non-Cash$1.2M
= Operating Cash Flow-$14.8M
- Capex-$4
= Free Cash Flow-$14.8M
Analysis
FY2025 free cash flow is -$14.8M. FCF conversion is 71.1% of net income. Operating cash flow was -$14.8M, with capex of -$4. The largest bridge item is Working Capital at $3.5M.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 8-K | Current report | Nov 13, 2026 | |
| 10-Q | Quarterly report | Nov 13, 2026 | |
| SC 13D/A | SC 13D/A filing | Oct 22, 2026 | |
| SC 13D/A | SC 13D/A filing | Oct 22, 2026 | |
| SC 13D/A | SC 13D/A filing | Oct 22, 2026 |
Does INDP generate free cash flow?
Indaptus Therapeutics, Inc. (INDP) generated -$14.82M of free cash flow in fiscal 2025.
How much operating cash flow does INDP produce?
Operating cash flow was -$14.82M, before capital expenditures of $4.00.
Continue the stock analysis
Jump to another research area for this company.